Hancock Jaffe Announces Positive Nasdaq Listing Determination
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) has received an extension from the Nasdaq Hearings Panel allowing it to continue listing on The Nasdaq Capital Market until December 28, 2020. This extension enables the company to demonstrate compliance with the minimum $1.00 bid price requirement by achieving a closing bid price of at least $1.00 for 10-20 consecutive business days. HJLI is actively taking steps to meet these requirements and will update shareholders on its compliance efforts.
- Received extension for continued Nasdaq listing until December 28, 2020.
- Opportunity to comply with minimum bid price requirement.
- Company must achieve a minimum bid price of $1.00 within a specified timeframe to maintain listing.
Extension Granted for Continued Listing
IRVINE, CA / ACCESSWIRE / September 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Capital Market pursuant to an extension through December 28, 2020, to evidence compliance with the minimum
To evidence compliance with the rule, the Company must evidence a closing bid price of at least
About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraftÒ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. For more information, please visit HancockJaffe.com.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our first-in-human VenoValve study) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
SOURCE: Hancock Jaffe Laboratories, Inc.
View source version on accesswire.com:
https://www.accesswire.com/606934/Hancock-Jaffe-Announces-Positive-Nasdaq-Listing-Determination
FAQ
What is the current status of Hancock Jaffe Laboratories' Nasdaq listing?
What are the compliance requirements for HJLI to stay listed on Nasdaq?
What steps is Hancock Jaffe Laboratories taking to comply with Nasdaq requirements?
When is the deadline for HJLI to meet Nasdaq's bid price requirement?
